Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Relationship between initiation of 340B participation and hospital safety-net engagement.

Nikpay SS, Buntin MB, Conti RM.

Health Serv Res. 2020 Apr;55(2):157-169. doi: 10.1111/1475-6773.13278.

PMID:
32187392
2.

Pediatric Orphan Drug Indications: 2010-2018.

Kimmel L, Conti RM, Volerman A, Chua KP.

Pediatrics. 2020 Apr;145(4). pii: e20193128. doi: 10.1542/peds.2019-3128. Epub 2020 Mar 3.

PMID:
32127360
3.

Differences in the Receipt of Low-Value Services Between Publicly and Privately Insured Children.

Chua KP, Schwartz AL, Volerman A, Conti RM, Huang ES.

Pediatrics. 2020 Feb;145(2). pii: e20192325. doi: 10.1542/peds.2019-2325. Epub 2020 Jan 7.

PMID:
31911477
4.

Association of Opioid Prescribing Patterns With Prescription Opioid Overdose in Adolescents and Young Adults.

Chua KP, Brummett CM, Conti RM, Bohnert A.

JAMA Pediatr. 2019 Dec 16. doi: 10.1001/jamapediatrics.2019.4878. [Epub ahead of print]

PMID:
31841589
5.

Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017.

Chen AJ, Hu X, Conti RM, Jena AB, Goldman DP.

Value Health. 2019 Dec;22(12):1387-1395. doi: 10.1016/j.jval.2019.08.005. Epub 2019 Sep 23.

PMID:
31806195
6.

ASHP Foundation Pharmacy Forecast 2020: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems.

Vermeulen LC, Swarthout MD, Alexander GC, Ginsburg DB, Pritchett KO, White SJ, Tryon J, Emmerich C, Nesbit TW, Greene W, Fox ER, Conti RM, Scott BE, Sheehy F, Melby MJ, Lantzy MA, Hoffman JM, Knoer S, Zellmer WA.

Am J Health Syst Pharm. 2020 Jan 8;77(2):84-112. doi: 10.1093/ajhp/zxz283. No abstract available.

PMID:
31803902
7.

Revenues and Profits From Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016.

Conti RM, Nikpay SS, Buntin MB.

JAMA Netw Open. 2019 Oct 2;2(10):e1914141. doi: 10.1001/jamanetworkopen.2019.14141.

8.

Financial Toxicity of Prescription Drugs.

Conti RM.

Ann Intern Med. 2019 Oct 1. doi: 10.7326/M19-2899. [Epub ahead of print] No abstract available.

PMID:
31569210
9.

Concentrations of macronutrients, minerals and heavy metals in home-prepared diets for adult dogs and cats.

Pedrinelli V, Zafalon RVA, Rodrigues RBA, Perini MP, Conti RMC, Vendramini THA, de Carvalho Balieiro JC, Brunetto MA.

Sci Rep. 2019 Sep 10;9(1):13058. doi: 10.1038/s41598-019-49087-z.

10.

Pharmacy Benefit Manager Reform: Lessons From Ohio.

Royce TJ, Kircher S, Conti RM.

JAMA. 2019 Jun 20. doi: 10.1001/jama.2019.7104. [Epub ahead of print] No abstract available.

PMID:
31219507
11.

Effects of different sources and levels of copper on lipid metabolism in Merino × Texel lambs.

Garrine CMLP, Yoshikawa CYC, Conti RMC, Correa LB, Pugine SMP, Tchamo C, Pondja A, de Carvalho Balieiro JC, Zanetti MA.

Meat Sci. 2019 Sep;155:85-90. doi: 10.1016/j.meatsci.2019.04.021. Epub 2019 Apr 25.

PMID:
31100641
12.

Assessment of Prescriber and Pharmacy Shopping Among the Family Members of Patients Prescribed Opioids.

Chua KP, Brummett CM, Conti RM, Haffajee RL, Prosser LA, Bohnert ASB.

JAMA Netw Open. 2019 May 3;2(5):e193673. doi: 10.1001/jamanetworkopen.2019.3673.

13.

Generic prescription drug price increases: which products will be affected by proposed anti-gouging legislation?

Conti RM, Nguyen KH, Rosenthal MB.

J Pharm Policy Pract. 2018 Nov 21;11:29. doi: 10.1186/s40545-018-0156-8. eCollection 2018.

14.

Out-of-pocket Spending on Orphan Drug Prescriptions Among Commercially Insured Adults in 2014.

Chua KP, Conti RM.

J Gen Intern Med. 2019 Mar;34(3):338-340. doi: 10.1007/s11606-018-4694-1. No abstract available.

15.

Diversity of Participants in the 340B Drug Pricing Program for US Hospitals.

Nikpay S, Buntin M, Conti RM.

JAMA Intern Med. 2018 Aug 1;178(8):1124-1127. doi: 10.1001/jamainternmed.2018.2015. No abstract available.

16.

The generic drug user fee amendments: an economic perspective.

Berndt ER, Conti RM, Murphy SJ.

J Law Biosci. 2018 Apr 11;5(1):103-141. doi: 10.1093/jlb/lsy002. eCollection 2018 May.

17.

Appropriately Framing Child Health Care Spending: A Prerequisite for Value Improvement.

Chua KP, Conti RM, Freed GL.

JAMA. 2018 Mar 20;319(11):1087-1088. doi: 10.1001/jama.2018.0014. No abstract available.

PMID:
29482195
18.

Effect of FDA Investigation on Opioid Prescribing to Children After Tonsillectomy/Adenoidectomy.

Chua KP, Shrime MG, Conti RM.

Pediatrics. 2017 Dec;140(6). pii: e20171765. doi: 10.1542/peds.2017-1765. Epub 2017 Nov 16.

19.

Biosimilars: Reimbursement Issues in Your Oncology Practice.

Conti RM.

J Oncol Pract. 2017 Sep;13(9_suppl):12s-14s. doi: 10.1200/JOP.2017.025783. No abstract available.

PMID:
28898590
20.

Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending.

Dusetzina SB, Conti RM, Yu NL, Bach PB.

JAMA Intern Med. 2017 Aug 1;177(8):1185-1188. doi: 10.1001/jamainternmed.2017.1885.

21.

Out-of-Pocket Spending Among Commercially Insured Patients for Epinephrine Autoinjectors Between 2007 and 2014.

Chua KP, Conti RM.

JAMA Intern Med. 2017 May 1;177(5):736-739. doi: 10.1001/jamainternmed.2017.0252. No abstract available.

22.

Policy Diffusion across Disparate Disciplines: Private- and Public-Sector Dynamics Affecting State-Level Adoption of the ACA.

Conti RM, Jones DK.

J Health Polit Policy Law. 2017 Apr;42(2):377-385. doi: 10.1215/03616878-3766771. Epub 2016 Dec 22.

PMID:
28007793
23.

Use of Low-Value Pediatric Services Among the Commercially Insured.

Chua KP, Schwartz AL, Volerman A, Conti RM, Huang ES.

Pediatrics. 2016 Dec;138(6). pii: e20161809. Erratum in: Pediatrics. 2017 Mar;139(3):null.

24.

Mitigating Financial Toxicity Among US Patients With Cancer.

de Souza JA, Conti RM.

JAMA Oncol. 2017 Jun 1;3(6):765-766. doi: 10.1001/jamaoncol.2016.4850. No abstract available.

PMID:
27893021
25.

21st century pharmacovigilance: efforts, roles, and responsibilities.

Pitts PJ, Louet HL, Moride Y, Conti RM.

Lancet Oncol. 2016 Nov;17(11):e486-e492. doi: 10.1016/S1470-2045(16)30312-6. Review.

PMID:
27819246
26.

Pharmaceuticals and Public Health.

Conti RM, Gee RE, Sharfstein JM.

JAMA. 2016 Nov 22;316(20):2083-2084. doi: 10.1001/jama.2016.15397. No abstract available.

PMID:
27768172
27.

A Pathway Through the Bundle Jungle.

Polite B, Ward JC, Cox JV, Morton RF, Hennessy J, Page R, Conti RM.

J Oncol Pract. 2016 Jun;12(6):504-9. doi: 10.1200/JOP.2015.008789. Epub 2016 May 12. Review. No abstract available.

PMID:
27173604
28.

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.

Padula WV, Larson RA, Dusetzina SB, Apperley JF, Hehlmann R, Baccarani M, Eigendorff E, Guilhot J, Guilhot F, Hehlmann R, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Saussele S, Schiffer CA, Silver RT, Simonsson B, Conti RM.

J Natl Cancer Inst. 2016 Mar 4;108(7). doi: 10.1093/jnci/djw003. Print 2016 Jul.

29.

Pharmaceutical Policy Reform--Balancing Affordability with Incentives for Innovation.

Conti RM, Rosenthal MB.

N Engl J Med. 2016 Feb 25;374(8):703-6. doi: 10.1056/NEJMp1515068. No abstract available.

PMID:
26933845
30.

Overspending driven by oversized single dose vials of cancer drugs.

Bach PB, Conti RM, Muller RJ, Schnorr GC, Saltz LB.

BMJ. 2016 Feb 29;352:i788. doi: 10.1136/bmj.i788. No abstract available.

31.

National Economic Conditions and Patient Insurance Status Predict Prostate Cancer Diagnosis Rates and Management Decisions.

Weiner AB, Conti RM, Eggener SE.

J Urol. 2016 May;195(5):1383-1389. doi: 10.1016/j.juro.2015.12.071. Epub 2015 Dec 18.

PMID:
26707507
32.

How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab.

Dusetzina SB, Ellis S, Freedman RA, Conti RM, Winn AN, Chambers JD, Alexander GC, Huskamp HA, Keating NL.

J Oncol Pract. 2015 Jul;11(4):313-8. doi: 10.1200/JOP.2015.004218. Epub 2015 Jun 9.

33.

Reform of the Buy-and-Bill System for Outpatient Chemotherapy Care Is Inevitable: Perspectives from an Economist, a Realpolitik, and an Oncologist.

Polite B, Conti RM, Ward JC.

Am Soc Clin Oncol Educ Book. 2015:e75-80. doi: 10.14694/EdBook_AM.2015.35.e75.

34.

Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.

Conti RM, Padula WV, Larson RA.

Ann Hematol. 2015 Apr;94 Suppl 2:S249-57. doi: 10.1007/s00277-015-2319-x. Epub 2015 Mar 27. Review.

35.

Reply to M. Thompson et Al.

Polite B, Ward JC, Cox JV, Morton RF, Hennessy J, Page R, Conti RM.

J Oncol Pract. 2015 May;11(3):263-4. doi: 10.1200/JOP.2015.003897. Epub 2015 Mar 3. No abstract available.

PMID:
25736384
36.

Pricing in the Market for Anticancer Drugs.

Howard DH, Bach PB, Berndt ER, Conti RM.

J Econ Perspect. 2015;29(1):139-62. No abstract available.

PMID:
28441702
38.

Payment for oncolytics in the United States: a history of buy and bill and proposals for reform.

Polite BN, Ward JC, Cox JV, Morton RF, Hennessy J, Page RD, Conti RM.

J Oncol Pract. 2014 Nov;10(6):357-62. doi: 10.1200/JOP.2014.001958. No abstract available.

39.

Improving outpatient oncology practice: several steps into a long journey.

Conti RM, Bach PB.

J Oncol Pract. 2014 Nov;10(6):355-6. doi: 10.1200/JOP.2014.000604. Epub 2014 Oct 14. No abstract available.

40.

The 340B drug discount program: hospitals generate profits by expanding to reach more affluent communities.

Conti RM, Bach PB.

Health Aff (Millwood). 2014 Oct;33(10):1786-92. doi: 10.1377/hlthaff.2014.0540.

41.

National trends in spending on and use of oral oncologics, first quarter 2006 through third quarter 2011.

Conti RM, Fein AJ, Bhatta SS.

Health Aff (Millwood). 2014 Oct;33(10):1721-7. doi: 10.1377/hlthaff.2014.0001.

42.

Antidepressant treatment and suicide attempts and self-inflicted injury in children and adolescents.

Gibbons RD, Coca Perraillon M, Hur K, Conti RM, Valuck RJ, Brent DA.

Pharmacoepidemiol Drug Saf. 2015 Feb;24(2):208-14. doi: 10.1002/pds.3713. Epub 2014 Sep 29.

43.

Eliminate cost-plus reimbursement for drugs.

Conti RM.

Clin Adv Hematol Oncol. 2014 Jan;12(1):66. No abstract available.

PMID:
25129910
44.

Problems with public reporting of cancer quality outcomes data.

Goldberg P, Conti RM.

J Oncol Pract. 2014 May;10(3):215-8. doi: 10.1200/JOP.2014.001405. No abstract available.

45.

Drug discount program--reply.

Conti RM.

JAMA. 2013 Oct 16;310(15):1627. doi: 10.1001/jama.2013.276770. No abstract available.

PMID:
24129474
46.

Cost consequences of the 340B drug discount program.

Conti RM, Bach PB.

JAMA. 2013 May 15;309(19):1995-6. doi: 10.1001/jama.2013.4156. No abstract available.

47.

The impact of emerging safety and effectiveness evidence on the use of physician-administered drugs: the case of bevacizumab for breast cancer.

Conti RM, Dusetzina SB, Herbert AC, Berndt ER, Huskamp HA, Keating NL.

Med Care. 2013 Jul;51(7):622-7. doi: 10.1097/MLR.0b013e318290216f.

48.

Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists.

Conti RM, Bernstein AC, Villaflor VM, Schilsky RL, Rosenthal MB, Bach PB.

J Clin Oncol. 2013 Mar 20;31(9):1134-9. doi: 10.1200/JCO.2012.42.7252. Epub 2013 Feb 19.

49.

Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008.

Kornfield R, Watson S, Higashi AS, Conti RM, Dusetzina SB, Garfield CF, Dorsey ER, Huskamp HA, Alexander GC.

Psychiatr Serv. 2013 Apr 1;64(4):339-46. doi: 10.1176/appi.ps.201200147.

50.

How do initial signals of quality influence the diffusion of new medical products? The case of new cancer drug treatments.

Conti RM, Bernstein A, Meltzer DO.

Adv Health Econ Health Serv Res. 2012;23:123-48.

PMID:
23156663

Supplemental Content

Loading ...
Support Center